THE England and Wales Cricket Board (ECB) has defended its stance on diversity and equality after West Indies great Michael Holding criticised England and Australia for not taking a knee in support of the "Black Lives Matter" movement during their ongoing limited-overs series.
England wore "Black Lives Matter" logos on their shirts during their test series against West Indies and took the knee to protest against racism, but opted not to continue the practice in subsequent series against Pakistan and Australia.
"Now that the West Indies team has gone home, that doesn't mean that you still shouldn't be respecting the message and what it stands for," Holding told Sky Sports.
"Yes, (racism) is more acute in the United States than in most other places but people around the entire world took on the mantle of spreading the word and getting this message out that it is time for equality and time for equal justice.
"It was no longer just a black versus white thing... so for Pakistan and England not to then take that signal... neither team did it... and the ECB came out with a pretty lame statement, as far as I am concerned."
Holding stressed that he wasn't trying to "force anyone" to take a knee, but wanted to keep the anti-racism message going.
Before the current series began, Australia skipper Aaron Finch said his team would not take the knee because "education is more important than the protest".
The ECB issued a statement in response to former fast bowler Holding's comments.
"Our response to the Black Lives Matter debate has been to view the issue alongside the whole inclusion and diversity space, to ensure that long-term and sustainable change happens for all communities who are not treated equally," it read.
"Our refreshed inclusion and diversity strategy, published at the start of the West Indies series, commits to several comprehensive initiatives that focus on eliminating discrimination from all areas of cricket.
"England's men's and women's players all remain committed to using their reach and influence to keep promoting inclusion and diversity in perpetuity, for the betterment of cricket and sport. We understand the importance of symbolism, and its power to keep an issue high on the agenda. Our goal is to ensure we deliver both reach and change."
Holding took issue with Finch's comments, saying that raising awareness and education were both important tools in the fight for equality.
"(Finch) is saying that he's glad he is part of a sport where no one is barred from playing, irrespective of your race, your gender, your ethnicity, your religion," Holding added.
"Well, I don't know any sport where anyone is barred from playing because of anything at all. So that's a pretty lame statement."
Former West Indies skipper Daren Sammy also recently spoken out on equality issues, urging cricket's governing bodies to treat racism more seriously and pay it the same attention they give to upholding the integrity of the game.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.